Document Detail


Zoledronic acid treatment in children with osteogenesis imperfecta.
MedLine Citation:
PMID:  21293106     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Intravenous disodium pamidronate has become an established treatment in osteogenesis imperfecta (OI). Another bisphosphonate, zoledronic acid, has been indicated for the treatment of adult osteoporosis. We studied its efficacy and safety in children with mild OI.
METHODS: Patients were treated for 1.0-3.2 years with 0.05 mg/kg zoledronic acid intravenously every 6 months as part of their clinical care. They were carefully followed for clinical and biochemical parameters, side effects, bone mineral densities (BMD) and compression fractures.
RESULTS: The study included 17 patients (age 1.5-16.8 years) with type I OI. They had sustained altogether 73 fractures; 9 had compression fractures. During the treatment, 6 patients suffered in total 10 new long-bone fractures. The median lumbar spine areal BMD z-score increased from -2.0 to -0.7 during 2 years of treatment. The infusions were associated with a transient decrease in serum calcium and phosphate and a significant increase in serum PTH. Two patients developed symptomatic hypocalcemia. Bone turnover markers decreased during the treatment.
CONCLUSIONS: Intravenous zoledronic acid is an effective mode of treatment in children with OI. The treatment response is comparable to pamidronate but the infusion protocol is more convenient. Further studies are needed to establish optimal dosing and long-term safety.
Authors:
Ilkka Vuorimies; Sanna Toiviainen-Salo; Matti Hero; Outi Mäkitie
Related Documents :
21473456 - Combination of platelet-rich plasma with degradable bioactive borate glass for segmenta...
21207046 - Traumatic posterior atlantoaxial dislocation without associated fracture and neurologic...
18296296 - Calcium requirements for asian children and adolescents.
19877746 - Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy.
12112976 - Neuromuscular differences between male and female athletes.
16352626 - Delayed detection of cleft palate: an audit of newborn examination.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-02-02
Journal Detail:
Title:  Hormone research in pædiatrics     Volume:  75     ISSN:  1663-2826     ISO Abbreviation:  Horm Res Paediatr     Publication Date:  2011  
Date Detail:
Created Date:  2011-05-04     Completed Date:  2011-08-23     Revised Date:  2011-12-01    
Medline Journal Info:
Nlm Unique ID:  101525157     Medline TA:  Horm Res Paediatr     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  346-53     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Affiliation:
Hospital for Children and Adolescents, Pediatric Endocrinology and Metabolic Bone Diseases, University of Helsinki, Helsinki, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Bone Density / drug effects
Bone Density Conservation Agents / therapeutic use
Child
Child, Preschool
Diphosphonates / therapeutic use*
Female
Follow-Up Studies
Fractures, Bone / epidemiology,  prevention & control
Humans
Imidazoles / therapeutic use*
Infant
Lumbar Vertebrae / drug effects
Male
Osteogenesis Imperfecta / drug therapy*
Spinal Fractures / epidemiology,  prevention & control
Treatment Outcome
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid
Comments/Corrections
Comment In:
Horm Res Paediatr. 2011;76(4):291; author reply 292   [PMID:  21912084 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maternal Serum Adiponectin at 11-13 Weeks of Gestation in Pregnancies Delivering Small for Gestation...
Next Document:  Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehic...